Understanding Cerebral Ischemia-Reperfusion Injury and Neuroprotection

Acute ischemic stroke remains a primary driver of adult mortality and lasting neurological disability across the globe. Clinicians rapidly restore arterial perfusion using intravenous thrombolysis or mechanical thrombectomy to salvage threatened cerebral tissue. However, abrupt reoxygenation paradoxically triggers secondary tissue destruction known as cerebral ischemia-reperfusion injury. This pathological condition intensifies cellular apoptosis, microvascular failure, and neuroinflammation throughout the vulnerable ischemic penumbra. Consequently, medical researchers actively investigate pharmacological compounds capable of shielding neuronal networks against acute reperfusion-induced damage.

Propofol serves as an established intravenous anesthetic agent widely utilized in operating theatres and intensive care units worldwide. Beyond its recognized sedation properties through gamma-aminobutyric acid receptor modulation, accumulating evidence indicates that propofol exerts substantial neuroprotective actions. Specifically, the drug mitigates oxidative stress, reduces neuronal apoptosis, and preserves cerebral microcirculation during severe metabolic crises. Nevertheless, the precise regulatory molecules underlying these cytoprotective actions have remained incompletely understood until recently. Investigating these distinct molecular pathways clarifies how propofol protects vulnerable brain parenchyma. A thorough mechanistic understanding enables neurocritical care clinicians to tailor anesthesia regimens, potentially improving functional independence and long-term recovery for stroke patients.

Evaluating In Vitro Models of Reperfusion-Induced Cellular Injury

To investigate the mechanistic underpinnings of propofol in post-ischemic neuronal recovery, researchers created a robust in vitro reperfusion paradigm. They cultured human neuroblastoma SK-N-SH cells under strict oxygen-glucose deprivation followed by reoxygenation, thereby replicating ischemic insult and subsequent arterial recanalization. The authors exposed these damaged cells to graduated concentrations of propofol to evaluate concentration-dependent cytoprotection. Multiple biochemical assays quantified cell viability, membrane integrity, and markers of programmatic cellular demise.

The findings demonstrated clear therapeutic benefits following propofol exposure. Cell Counting Kit-8 evaluations indicated that propofol significantly enhanced neuronal survival following hypoxic stress. Furthermore, terminal deoxynucleotidyl transferase dUTP nick end labeling staining confirmed a significant drop in apoptotic cell counts compared to untreated cells. Enzyme-linked immunosorbent assays demonstrated that propofol markedly repressed the release of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha and interleukin-1 beta. Additionally, the anesthetic suppressed intracellular reactive oxygen species accumulation while restoring endogenous antioxidant superoxide dismutase activity. These collective observations illustrate that propofol arrests the self-amplifying cascade of inflammation and oxidative damage. Consequently, these cellular data establish a clear empirical foundation for elucidating the deeper genetic and proteomic targets responsive to propofol administration.

Unraveling the NEDD4L and HTR2B Ubiquitination Pathway

To identify the molecular receptors engaged by propofol, investigators deployed the SwissTargetPrediction computational database. This bioinformatic screening identified 5-hydroxytryptamine receptor 2B, designated as HTR2B, as a primary candidate target. Subsequent quantitative reverse transcription polymerase chain reaction and Western blotting demonstrated that oxygen-glucose deprivation markedly elevated HTR2B expression. In contrast, propofol administration downregulated HTR2B transcript and protein levels in a clear dose-dependent pattern, suggesting that HTR2B suppression aids cell survival.

The investigators then explored the post-translational mechanisms governing HTR2B protein stability. Utilizing the UbiBrowser algorithm, they predicted that neural precursor cell expressed developmentally down-regulated 4-like, an E3 ubiquitin ligase termed NEDD4L, targets HTR2B. Co-immunoprecipitation experiments confirmed that NEDD4L physically binds to HTR2B, inducing its polyubiquitination and directing it toward 26S proteasomal degradation. Furthermore, administering the proteasome inhibitor MG132 halted propofol-mediated HTR2B degradation, verifying proteasome involvement. Cycloheximide chase assays also confirmed that NEDD4L shortens HTR2B protein half-life. Conversely, genetic knockdown of NEDD4L prevented propofol from reducing HTR2B levels, abolishing its neuroprotective actions. Therefore, propofol protects ischemic neurons primarily by upregulating NEDD4L, which accelerates the ubiquitination and clearance of deleterious and harmful HTR2B receptors.

Preserving Mitochondrial Polarization and Mitigating Oxidative Stress

Mitochondrial stability represents the cornerstone of neuronal viability during acute ischemic challenges. Reperfusion promotes abrupt calcium entry into cells, destabilizing mitochondrial inner membranes and triggering destructive permeability transition pores. In this investigation, researchers monitored mitochondrial membrane potential using JC-1 fluorometric dye staining. Cells exposed to reoxygenation without intervention exhibited marked membrane depolarization, which signifies critical mitochondrial collapse and bioenergetic breakdown.

Encouragingly, propofol administration preserved mitochondrial membrane polarization in a concentration-dependent fashion. By stimulating NEDD4L-dependent HTR2B ubiquitination, propofol blocked mitochondrial pore opening, thereby maintaining adequate intracellular adenosine triphosphate synthesis. Moreover, stabilized mitochondria generated significantly fewer toxic reactive oxygen and nitrogen radicals. Western blot evaluations demonstrated that propofol downregulated the apoptotic executioner cleaved caspase-3 and pro-apoptotic Bax, while significantly increasing protective Bcl-2 protein concentrations. Consequently, neuronal cells preserved their bioenergetic competence and resisted apoptotic disintegration despite severe reperfusion stress. These results confirm that propofol shields mitochondria from oxidative degradation by regulating upstream receptor turnover. Thus, targeting the NEDD4L and HTR2B axis directly prevents the metabolic collapse that transforms salvageable penumbral brain tissue into permanently injured and infarcted necrotic brain tissue.

Translational Evidence and Clinical Perspectives in Neurocritical Care

To confirm these cellular discoveries within live physiological systems, researchers established an in vivo middle cerebral artery occlusion model in rodents. They subjected animals to temporary focal ischemia followed by arterial reperfusion, closely reflecting acute ischemic stroke management in humans. Investigators administered propofol intravenously following reperfusion onset to examine its therapeutic potential. Animals receiving propofol exhibited significantly diminished cerebral infarct sizes on triphenyltetrazolium chloride staining alongside substantially improved neurological functional deficit scores.

Histological analyses revealed that propofol effectively protected cortical tissue architecture, suppressed microglial activation, and curbed neuronal apoptotic death in ischemic regions. Mechanistically, brain homogenates from treated animals showed elevated NEDD4L levels and reduced HTR2B abundance, mirroring the in vitro findings. Importantly, experimental silencing of NEDD4L in vivo reversed these protective benefits, expanding infarct volumes and worsening behavioral deficits. Clinically, these findings provide compelling scientific support for using propofol in neurocritical care and neuroanesthesia settings. When managing patients undergoing mechanical thrombectomy or cerebral revascularization, anesthesiologists must balance systemic blood pressure with neuroprotective efficacy. Understanding how propofol modulates ubiquitin-mediated receptor breakdown encourages future clinical trials exploring tailored dosing strategies. Ultimately, these translational insights help clinicians optimize perioperative protocols, potentially preserving neurological function in severe stroke patients.

Frequently Asked Questions

Explore concise answers to prominent clinical questions regarding propofol, neuroprotection, and receptor degradation mechanisms during cerebral reperfusion injury.

How does propofol modulate the NEDD4L and HTR2B axis during reperfusion?

Propofol enhances the cellular activity and expression of the E3 ubiquitin ligase NEDD4L within post-ischemic neurons. Subsequently, NEDD4L physically binds to the 5-hydroxytryptamine receptor 2B, catalyzing its polyubiquitination. This biochemical tag directs HTR2B toward rapid proteasomal degradation, substantially lowering receptor abundance. Consequently, downregulating HTR2B halts deleterious downstream intracellular signaling, curbs inflammatory cytokine generation, limits neuronal apoptosis, and preserves mitochondrial polarization during acute reoxygenation stress.

Why is mitochondrial stability critical in acute cerebral ischemia?

Mitochondria regulate energy synthesis and control endogenous cellular apoptotic pathways in brain tissue. During acute ischemia and subsequent reperfusion, intracellular calcium overload and reactive oxygen species destroy the mitochondrial membrane potential. This collapse unleashes cytochrome c into the cytoplasm, which rapidly triggers caspase activation and irreversible cell death. Consequently, preserving mitochondrial membrane integrity and bioenergetic function prevents metabolic crisis, curbs excessive free radical production, and rescues vulnerable ischemic penumbral tissue.

What are the translational clinical perspectives of these findings?

These findings provide a clear molecular rationale for administering propofol during acute neurovascular recanalization, endovascular thrombectomy, and neurocritical care sedation. Understanding that the NEDD4L and HTR2B axis governs neuronal survival enables clinicians to explore targeted therapeutic protocols that maximize neuroprotection. Moreover, researchers can design novel pharmacotherapies that selectively inhibit HTR2B or upregulate NEDD4L ubiquitin ligase activity, potentially delivering neuroprotection in non-surgical stroke patients without inducing general anesthesia or hemodynamic instability.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang W et al. Propofol alleviates OGD/R-induced cerebral ischemia-reperfusion injury-related neuronal injury by regulating NEDD4L-mediated ubiquitination of HTR2B. Biochem Biophys Res Commun. 2026 Oct 22. doi: undefined. PMID: 42748874.


2. Wang H, Dong Y, Liu J. Mechanisms of Action of Propofol in Modulating Microglial Activation in Ischemic Stroke. Brain Res Bull. 2025;210:110932.


3. Li X, Han X, Wu Z. Propofol attenuates cerebral ischemia-reperfusion-mediated neuronal apoptosis and oxidative damage by regulating the miR-6838-5p/AQP11 axis. Arch Med Sci. 2024;20(3):890-899.


4. Sun H, Wang Y, Zhang W. Propofol protects against cerebral ischemia/reperfusion injury by down-regulating long noncoding RNA SNHG14. Eur Rev Med Pharmacol Sci. 2021;25(16):5120-5129.